Vav1 is Essential for HIF-1α Activation via a Lysosomal VEGFR1-Mediated Degradation Mechanism in Endothelial Cells.

HIF-1α VEGFR Vav1 endothelial cell hypoxia protein degradation

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
27 May 2020
Historique:
received: 23 04 2020
revised: 24 05 2020
accepted: 25 05 2020
entrez: 31 5 2020
pubmed: 31 5 2020
medline: 31 5 2020
Statut: epublish

Résumé

The vascular response to hypoxia and ischemia is essential for maintaining homeostasis during stressful conditions and is particularly critical for vital organs such as the heart. Hypoxia-inducible factor-1 (HIF-1) is a central regulator of the response to hypoxia by activating transcription of numerous target genes, including vascular endothelial growth factor (VEGF). Here we identify the guanine nucleotide exchange factor (GEF) Vav1, a regulator of the small Rho-GTPase and cell signaling in endothelial cells, as a key vascular regulator of hypoxia. We show that Vav1 is present in the vascular endothelium and is essential for HIF-1 activation under hypoxia. So, we hypothesized that Vav1 could be a key regulator of HIF-1 signaling. In our findings, Vav1 regulates HIF-1α stabilization through the p38/Siah2/PHD3 pathway. In normoxia, Vav1 binds to vascular endothelial growth factor receptor 1 (VEGFR1), which directs Vav1 to lysosomes for degradation. In contrast, hypoxia upregulates Vav1 protein levels by inhibiting lysosomal degradation, which is analogous to HIF-1α regulation by hypoxia: both proteins are constitutively produced and degraded in normoxia allowing for a rapid response when stress occurs. Consequently, hypoxia rapidly stabilizes Vav1, which is required for HIF-1α accumulation. This shows that Vav1 is the key mediator controlling the stabilization of HIF1α in hypoxic conditions. With this finding, we report a novel pathway to stabilize HIF-1, which shows a possible reason why clinical trials targeting HIF-1 has not been effective. Targeting Vav1 can be the new approach to overcome hypoxic tumors.

Identifiants

pubmed: 32471123
pii: cancers12061374
doi: 10.3390/cancers12061374
pmc: PMC7352305
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Nat Rev Mol Cell Biol. 2005 Jan;6(1):79-87
pubmed: 15688069
J Biol Chem. 2006 Nov 17;281(46):35316-26
pubmed: 17003045
Mol Cell Biol. 2005 Jun;25(12):4853-62
pubmed: 15923604
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
Nature. 1995 Mar 30;374(6521):470-3
pubmed: 7700359
Genesis. 2002 Dec;34(4):251-6
pubmed: 12434335
Dev Cell. 2013 Mar 25;24(6):573-85
pubmed: 23537630
Nature. 2006 May 25;441(7092):437-43
pubmed: 16724055
J Biochem. 2013 Jan;153(1):13-9
pubmed: 23172303
Mol Biotechnol. 2013 Nov;55(3):217-26
pubmed: 23709336
Nat Rev Immunol. 2002 Jul;2(7):476-86
pubmed: 12094222
J Cell Mol Med. 2010 Mar;14(3):528-52
pubmed: 19840194
Cancers (Basel). 2019 Oct 25;11(11):
pubmed: 31717697
Mol Cell Biol. 1994 Apr;14(4):2777-85
pubmed: 7511210
Immunol Rev. 2003 Apr;192:42-52
pubmed: 12670394
Immunity. 1997 Oct;7(4):451-60
pubmed: 9354466
Mol Cancer Res. 2009 Apr;7(4):443-51
pubmed: 19372575
J Biol Chem. 1981 Apr 25;256(8):3858-64
pubmed: 7217060
Am J Physiol Lung Cell Mol Physiol. 2002 Jun;282(6):L1324-9
pubmed: 12003789
FEBS Lett. 2018 Jul;592(13):2199-2212
pubmed: 29790151
Nature. 1995 Mar 30;374(6521):474-7
pubmed: 7700360
Mol Cell Biol. 2000 Mar;20(5):1461-77
pubmed: 10669724
Front Oncol. 2019 Mar 20;9:171
pubmed: 30949450
J Biol Chem. 2000 Jun 16;275(24):18160-71
pubmed: 10849438
Proc Natl Acad Sci U S A. 1977 Jan;74(1):54-8
pubmed: 264694
Cell. 1996 Jan 26;84(2):277-87
pubmed: 8565073
Cancer Cell. 2004 Nov;6(5):485-95
pubmed: 15542432
Cell. 2007 Aug 24;130(4):691-703
pubmed: 17719546

Auteurs

Jaewoo Hong (J)

Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21704, USA.

Yongfen Min (Y)

Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21704, USA.

Todd Wuest (T)

Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21704, USA.

P Charles Lin (PC)

Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21704, USA.

Classifications MeSH